Share this article
Share this article
ResearchAndMarkets.com s offering.
This report highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030.
The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.
The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.
Global Increase in Mental Health Burden
Market Challenges
Lack of Awareness for Precision Psychiatry Diagnostics
Market Opportunities
Massive Scope for Adoption of NGS-Based Genetic Tests in Emerging Markets
Key Companies Profiled
Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, Centogene N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, PreventionGenetics
Key Questions Answered in this Report:
How is precision psychiatry revolutionizing the field of mental health diagnostics?
What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?